Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cellectar Biosciences, Inc.CLRB · Entity 7572 | Director | June 24, 2020 | June 25, 2020 |
| GYRE THERAPEUTICS, INC.CBIO · Entity 5247 | Director | September 06, 2018 | September 07, 2018 |
| Lipocine Inc.LPCN · Entity 7696 | Director | December 16, 2020 | December 17, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cellectar Biosciences, Inc.
Report date June 24, 2020 · Filed June 25, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.28 · Expires 2030-06-24 | Direct | 50,000 |
Reported balance
After 2020-06-24 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-06-24 · Grant · Acquired 50,000 · Balance 50,000 F1: This option grant shall vest over a period of three years from the grant date, with one-third vesting on the first anniversary of the grant date and the remainder vesting in 24 equal monthly installments over a 24 month period beginning on the first anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: This option grant shall vest over a period of three years from the grant date, with one-third vesting on the first anniversary of the grant date and the remainder vesting in 24 equal monthly installments over a 24 month period beginning on the first anniversary of the grant date.
GYRE THERAPEUTICS, INC.
Report date September 06, 2018 · Filed September 07, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,190 |
Reported balance
After 2018-09-06 transaction · row 1
1 source rowRow 1 · 2018-09-06 · Disposition to issuer · Disposed 190 · Balance 1,190 |
Lipocine Inc.
Report date December 16, 2020 · Filed December 17, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 12,750 |
Reported balance
After 2020-12-16 transaction · row 1
1 source rowRow 1 · 2020-12-16 · Exercise / conversion · Acquired 7,500 · Balance 12,750 F1: Represents shares of Lipocine Inc. common stock ("LPCN Common Stock") acquired upon the vesting of restricted stock units. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2027-01-25 | Direct | 7,500 |
Reported balance
After 2020-12-16 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-12-16 · Exercise / conversion · Acquired 7,500 · Balance 7,500 F2: Subject to vesting whereby 1/4 of the shares subject to the award will vest on December 31, 2017 and the remaining 3/4 of the shares subject to the award will vest on the receipt by the Company of FDA approval of TLANDO. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of Lipocine Inc. common stock ("LPCN Common Stock") acquired upon the vesting of restricted stock units.
F2: Subject to vesting whereby 1/4 of the shares subject to the award will vest on December 31, 2017 and the remaining 3/4 of the shares subject to the award will vest on the receipt by the Company of FDA approval of TLANDO.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 16, 2020 Filed Dec 17, 2020 16:06 UTC | Lipocine Inc. LPCN · Entity 7696 | Exercise / conversionRestricted Stock Unit · Derivative | 7,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001638599-20-000978 · doc4_6961.xml · derivative · entry 2 HILL STEPHEN A · CIK 0001237404 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2027-01-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Subject to vesting whereby 1/4 of the shares subject to the award will vest on December 31, 2017 and the remaining 3/4 of the shares subject to the award will vest on the receipt by the Company of FDA approval of TLANDO. F2 · derivative.expiration_date: Subject to vesting whereby 1/4 of the shares subject to the award will vest on December 31, 2017 and the remaining 3/4 of the shares subject to the award will vest on the receipt by the Company of FDA approval of TLANDO. Read SEC document |
| December 16, 2020 Filed Dec 17, 2020 16:06 UTC | Lipocine Inc. LPCN · Entity 7696 | Exercise / conversionCommon Stock | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001638599-20-000978 · doc4_6961.xml · nonDerivative · entry 1 HILL STEPHEN A · CIK 0001237404 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,750 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents shares of Lipocine Inc. common stock ("LPCN Common Stock") acquired upon the vesting of restricted stock units. F1 · shares: Represents shares of Lipocine Inc. common stock ("LPCN Common Stock") acquired upon the vesting of restricted stock units. F1 · price: Represents shares of Lipocine Inc. common stock ("LPCN Common Stock") acquired upon the vesting of restricted stock units. Read SEC document |
| June 24, 2020 Filed Jun 25, 2020 20:22 UTC | Cellectar Biosciences, Inc. CLRB · Entity 7572 | GrantStock option (right to buy) · Derivative | 50,000 | $0.00 Strike: $1.28 | $0.00 |
DisclosureSEC source: 0001104659-20-076872 · m2023456d4_4.xml · derivative · entry 1 HILL STEPHEN A · CIK 0001237404 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2030-06-24 F1 · derivative.exercise_date: This option grant shall vest over a period of three years from the grant date, with one-third vesting on the first anniversary of the grant date and the remainder vesting in 24 equal monthly installments over a 24 month period beginning on the first anniversary of the grant date. Read SEC document |
| June 10, 2020 Filed Jun 10, 2020 16:11 UTC | Lipocine Inc. LPCN · Entity 7696 | GrantStock Options (Right to Buy) · Derivative | 22,000 | $0.96 Strike: $0.96 | $21,183.80 |
DisclosureSEC source: 0001638599-20-000593 · doc4_6751.xml · derivative · entry 1 HILL STEPHEN A · CIK 0001237404 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2030-06-10 F1 · derivative.exercise_date: 100% vesting one year from date of grant Read SEC document |
| June 04, 2020 Filed Jun 8, 2020 20:12 UTC | Cellectar Biosciences, Inc. CLRB · Entity 7572 | PurchaseCommon Stock | 18,000 | $1.08 | $19,438.20 |
DisclosureSEC source: 0001104659-20-070843 · tm2022064d4_4.xml · nonDerivative · entry 1 HILL STEPHEN A · CIK 0001237404 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Read SEC document |
| June 13, 2019 Filed Jun 14, 2019 20:32 UTC | Cellectar Biosciences, Inc. CLRB · Entity 7572 | GrantStock option (right to buy) · Derivative | 6,500 | $0.00 Strike: $2.15 | $0.00 |
DisclosureSEC source: 0001144204-19-031007 · tv523608_4.xml · derivative · entry 1 HILL STEPHEN A · CIK 0001237404 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,500 Underlying: Common Stock · 6,500 shares Expires 2029-06-13 F1 · derivative.exercise_date: Options vest on the one year anniversary of the date of grant. Read SEC document |
| June 12, 2019 Filed Jun 14, 2019 11:10 UTC | Lipocine Inc. LPCN · Entity 7696 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $1.68 Strike: $1.68 | $16,800.00 |
DisclosureSEC source: 0001638599-19-000610 · doc4_6152.xml · derivative · entry 1 HILL STEPHEN A · CIK 0001237404 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2029-06-12 F1 · derivative.exercise_date: 100% vesting one year from date of grant Read SEC document |
| November 29, 2018 Filed Nov 30, 2018 23:19 UTC | Cellectar Biosciences, Inc. CLRB · Entity 7572 | SaleWarrants · Derivative | 530 | $0.05 Strike: $468.00 | $27.03 |
DisclosureSEC source: 0001144204-18-062709 · tv508276_4.xml · derivative · entry 4 HILL STEPHEN A · CIK 0001237404 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 530 shares Expires 2019-08-20 Read SEC document |
| November 29, 2018 Filed Nov 30, 2018 23:19 UTC | Cellectar Biosciences, Inc. CLRB · Entity 7572 | SaleSeries A Warrants · Derivative | 9,390 | $0.10 Strike: $30.40 | $917.40 |
DisclosureSEC source: 0001144204-18-062709 · tv508276_4.xml · derivative · entry 3 HILL STEPHEN A · CIK 0001237404 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,390 shares Expires 2021-04-20 Read SEC document |
| November 29, 2018 Filed Nov 30, 2018 23:19 UTC | Cellectar Biosciences, Inc. CLRB · Entity 7572 | SaleCommon Stock | 53 | $2.21 | $117.13 |
DisclosureSEC source: 0001144204-18-062709 · tv508276_4.xml · nonDerivative · entry 2 HILL STEPHEN A · CIK 0001237404 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| November 29, 2018 Filed Nov 30, 2018 23:19 UTC | Cellectar Biosciences, Inc. CLRB · Entity 7572 | SaleCommon Stock | 939 | $2.21 | $2,075.28 |
DisclosureSEC source: 0001144204-18-062709 · tv508276_4.xml · nonDerivative · entry 1 HILL STEPHEN A · CIK 0001237404 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53 Read SEC document |
| October 12, 2018 Filed Oct 15, 2018 23:50 UTC | Cellectar Biosciences, Inc. CLRB · Entity 7572 | GrantStock option (right to buy) · Derivative | 13,000 | $0.00 Strike: $2.61 | $0.00 |
DisclosureSEC source: 0001144204-18-053880 · tv504845_form4.xml · derivative · entry 1 HILL STEPHEN A · CIK 0001237404 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,000 Underlying: Common Stock · 13,000 shares Expires 2028-10-12 F1 · derivative.exercise_date: This option grant was divided into a definitive grant of 6,150 shares, which vest in equal monthly installments over a seven month period from the grant date, and a contingent grant of 6,850 shares, which are subject to the following conditions: (i) approval by Cellectar's stockholders of an increase in shares available under the Amended and Restated 2015 Stock Incentive Plan at the Corporation's 2019 annual meeting of stockholders or other special meeting of stockholders called for such purpose; and (ii) to the extent stockholder approval is received, the contingent grant shall vest immediately upon such stockholder approval. Read SEC document |
| September 06, 2018 Filed Sep 7, 2018 01:41 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | Disposition to issuerCommon Stock | 190 | $10.07 | $1,913.30 |
DisclosureSEC source: 0001209191-18-049987 · doc4.xml · nonDerivative · entry 1 HILL STEPHEN A · CIK 0001237404 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,190 Read SEC document |
| June 27, 2018 Filed Jun 28, 2018 12:28 UTC | Lipocine Inc. LPCN · Entity 7696 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $1.33 Strike: $1.33 | $26,600.00 |
DisclosureSEC source: 0001638599-18-000697 · doc4_5499.xml · derivative · entry 1 HILL STEPHEN A · CIK 0001237404 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2028-06-27 F1 · derivative.exercise_date: 100% vesting one year from date of grant Read SEC document |
| June 13, 2018 Filed Jun 15, 2018 21:52 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | GrantStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $24.94 | $0.00 |
DisclosureSEC source: 0001209191-18-038135 · doc4.xml · derivative · entry 1 HILL STEPHEN A · CIK 0001237404 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2028-06-13 F1 · derivative.exercise_date: The option shall vest monthly over a period of 12 months commencing 06/13/2018. Read SEC document |
| February 20, 2018 Filed Feb 22, 2018 21:33 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | OtherRedeemable Convertible Note · Derivative | 21,600 | $0.00 Strike: $137.85 | $0.00 |
DisclosureSEC source: 0001209191-18-012438 · doc4.xml · derivative · entry 2 HILL STEPHEN A · CIK 0001237404 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 156 shares Expires not disclosed F1 · derivative.exercise_price: Reflects a 1:15 reverse stock split effected on February 10, 2017. F2 · kind: Reflects a redeemable convertible note of the Issuer (the "Note") that matured, with the face value of the Note repaid to the Reporting Person. F3 · derivative.exercise_date: At the option of the Reporting Person, at any time on or before February 19, 2018, the Note was redeemable into cash at a rate of $1 for each $1 principal amount of the Note or convertible into shares of common stock of the Issuer at a conversion rate of $137.85 per share, respectively. F4 · derivative.expiration_date: The Note matured on February 19, 2018. Read SEC document |
| February 20, 2018 Filed Feb 22, 2018 21:33 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | OtherRedeemable Convertible Note · Derivative | Not disclosed | $0.00 Strike: $137.85 | $189,000.00 |
DisclosureSEC source: 0001209191-18-012438 · doc4.xml · derivative · entry 1 HILL STEPHEN A · CIK 0001237404 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: Not disclosed Underlying: Common Stock · 1,371 shares Expires not disclosed F1 · derivative.exercise_price: Reflects a 1:15 reverse stock split effected on February 10, 2017. F2 · kind: Reflects a redeemable convertible note of the Issuer (the "Note") that matured, with the face value of the Note repaid to the Reporting Person. F3 · derivative.exercise_date: At the option of the Reporting Person, at any time on or before February 19, 2018, the Note was redeemable into cash at a rate of $1 for each $1 principal amount of the Note or convertible into shares of common stock of the Issuer at a conversion rate of $137.85 per share, respectively. F4 · derivative.expiration_date: The Note matured on February 19, 2018. Read SEC document |
| December 29, 2017 Filed Jan 2, 2018 18:15 UTC | Lipocine Inc. LPCN · Entity 7696 | Exercise / conversionRestricted Stock Unit · Derivative | 2,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001638599-18-000027 · doc4_5173.xml · derivative · entry 3 HILL STEPHEN A · CIK 0001237404 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common stock · 2,500 shares Expires 2027-01-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Subject to vesting whereby 1/4 of the shares subject to the award will vest on December 29, 2017 and the remaining 3/4 of the shares subject to the award will vest on the receipt by the Company of FDA approval of LPCN 1021. F4 · derivative.expiration_date: Subject to vesting whereby 1/4 of the shares subject to the award will vest on December 29, 2017 and the remaining 3/4 of the shares subject to the award will vest on the receipt by the Company of FDA approval of LPCN 1021. Read SEC document |
| December 29, 2017 Filed Jan 2, 2018 18:15 UTC | Lipocine Inc. LPCN · Entity 7696 | SaleCommon stock | 1,250 | $3.47 | $4,341.50 |
DisclosureSEC source: 0001638599-18-000027 · doc4_5173.xml · nonDerivative · entry 2 HILL STEPHEN A · CIK 0001237404 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,250 F2 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: Represents the weighted average price of shares sold at a price that ranged from $3.43-$3.54. Read SEC document |
| December 29, 2017 Filed Jan 2, 2018 18:15 UTC | Lipocine Inc. LPCN · Entity 7696 | Exercise / conversionCommon Stock | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001638599-18-000027 · doc4_5173.xml · nonDerivative · entry 1 HILL STEPHEN A · CIK 0001237404 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents shares of Lipocine Inc. common stock ("LPCN Common Stock") acquired upon the vesting of restricted stock units (see footnote 4). F1 · shares: Represents shares of Lipocine Inc. common stock ("LPCN Common Stock") acquired upon the vesting of restricted stock units (see footnote 4). F1 · price: Represents shares of Lipocine Inc. common stock ("LPCN Common Stock") acquired upon the vesting of restricted stock units (see footnote 4). Read SEC document |
| July 13, 2017 Filed Jul 14, 2017 20:52 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $4.40 | $0.00 |
DisclosureSEC source: 0001209191-17-045213 · doc4.xml · derivative · entry 1 HILL STEPHEN A · CIK 0001237404 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2027-07-13 F1 · derivative.exercise_date: The option shall vest monthly over a period of 12 months commencing June 15, 2017. Read SEC document |
| May 31, 2017 Filed Jun 1, 2017 22:04 UTC | Cellectar Biosciences, Inc. CLRB · Entity 7572 | GrantStock option (right to buy) · Derivative | 10,000 | $0.00 Strike: $1.74 | $0.00 |
DisclosureSEC source: 0001144204-17-030683 · v468272_4.xml · derivative · entry 1 HILL STEPHEN A · CIK 0001237404 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2027-05-31 F1 · derivative.exercise_date: Options vest in equal annual increments over a period of three years from the date of grant. Read SEC document |
| January 26, 2017 Filed Jan 30, 2017 21:40 UTC | Lipocine Inc. LPCN · Entity 7696 | GrantRestricted Stock Unit · Derivative | 10,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001638599-17-000128 · doc4_4499.xml · derivative · entry 1 HILL STEPHEN A · CIK 0001237404 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2027-01-25 F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of common stock upon vesting of the unit F2 · derivative.exercise_date: Subject to vesting whereby 1/4 of the shares subject to the award will vest on December 31, 2017 and the remaining 3/4 of the shares subject to the award will vest on the receipt by the Company of FDA approval of LPCN 1021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.